EGFR-targeted therapies in lung cancer: predictors of response and toxicity
about
Emerging Roles of MicroRNAs in EGFR-Targeted Therapies for Lung CancerMutations of the EPHB6 receptor tyrosine kinase induce a pro-metastatic phenotype in non-small cell lung cancerErlotinib in African Americans with advanced non-small cell lung cancer: a prospective randomized study with genetic and pharmacokinetic analyses.A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activityPharmacogenetics in Ghana: reviewing the evidence.Pathway profiling and rational trial design for studies in advanced stage cervical carcinoma: a review and a perspective.Photodynamic therapy-induced angiogenic signaling: consequences and solutions to improve therapeutic response.The BRAFT1799A mutation confers sensitivity of thyroid cancer cells to the BRAFV600E inhibitor PLX4032 (RG7204).Pharmacogenetics in breast cancer: steps toward personalized medicine in breast cancer managementEGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104.Incidence and risk of severe neutropenia in advanced cancer patients treated with cetuximab: a meta-analysisIncidence and risk of hypomagnesemia in advanced cancer patients treated with cetuximab: A meta-analysis.Insulin-like growth factor-1 receptor-targeted therapy for non-small cell lung cancer: a mini reviewRetargeted adenoviral cancer gene therapy for tumour cells overexpressing epidermal growth factor receptor or urokinase-type plasminogen activator receptorWhat's positive about 'triple-negative' breast cancer?Immunotherapy in the landscape of new targeted treatments for non-small cell lung cancer.Clinical pharmacology and pharmacogenetics in a genomics era: the DMET platform.Monoclonal antibodies in lung cancer.Fibulin-3-mediated inhibition of epithelial-to-mesenchymal transition and self-renewal of ALDH+ lung cancer stem cells through IGF1R signaling.EGFR signaling pathway and related-miRNAs in age-related diseases: the example of miR-221 and miR-222.The relationship of kinase insert domain receptor gene polymorphisms and clinical outcome in advanced hepatocellular carcinoma patients treated with sorafenib.Pharmacogenetic predictors for EGFR-inhibitor-associated skin toxicity.Rapid symptomatic improvement in gefitinib-treated patients with EGFR-mutated lung cancer: possible role of downregulation of inflammatory molecules?IL6 is associated with response to dasatinib and cetuximab: Phase II clinical trial with mechanistic correlatives in cetuximab-resistant head and neck cancer.Impact of heavy smoking on the benefits from first-line EGFR-TKI therapy in patients with advanced lung adenocarcinoma.
P2860
Q26798147-1FC70442-9F8E-4EC4-94E1-3DAA8ACB39A8Q30528942-FA3FC2DC-736F-477B-B43D-F49D38CB6198Q34266864-71B18635-F8DD-464F-B454-63DFB5D7C5EEQ35146077-EA564FB7-A6F5-4B5C-969E-8494B690FAD3Q35172002-509A6A6E-3105-4172-88D2-07C20C92FB0BQ35374477-7B2D9257-6BDD-4E37-BE61-5CC6550F08EAQ35766780-0D25CD0F-6F30-426D-B297-3B640817C292Q36130527-B01454B5-4E13-4087-B034-3278F825FB4EQ36441485-F7E0894E-4988-422F-8B8C-5D2DF4ACD61BQ36594155-02D06EFF-E120-4B95-90D9-C685866124A0Q36649908-652359B2-B998-4F10-9192-584FD9D359C3Q36980961-A5336D91-2055-430A-BD7F-E11EA8916521Q37418930-6B7EEC33-4161-425B-84DD-A039E3D8D9B7Q37513318-EEC3CD64-AB4B-44FD-831C-932176A7900AQ37605859-19A94A84-66FB-4727-AE9C-42C2F10C8DBEQ37619114-02E46E61-6600-4EDD-A4D6-7895AFCAA623Q37657540-E1AA8A18-23E8-4FD5-BF19-5662632D8F12Q38067454-08C59F1B-60F8-41F6-9432-AFC3ADBB9518Q39098768-92AAD73D-E34E-4F95-8FB6-95530952A9DEQ42396355-67D37BC3-9DC0-4DBD-B3ED-9A21E9CBF167Q44479261-29384C7C-C8E3-409D-A76E-3BEFC4432EB4Q44775271-8E468C1B-6EC1-4AC7-8A29-72B87A5C7707Q53197939-6547F293-C7BC-4A42-AAC0-27C7C9FFE58EQ53258023-40A01401-FBEB-4EA6-80EC-20909D5FE532Q54123954-BB0C18FA-DB08-4183-A5A1-F7847DBA2009
P2860
EGFR-targeted therapies in lung cancer: predictors of response and toxicity
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
EGFR-targeted therapies in lung cancer: predictors of response and toxicity
@en
EGFR-targeted therapies in lung cancer: predictors of response and toxicity.
@nl
type
label
EGFR-targeted therapies in lung cancer: predictors of response and toxicity
@en
EGFR-targeted therapies in lung cancer: predictors of response and toxicity.
@nl
prefLabel
EGFR-targeted therapies in lung cancer: predictors of response and toxicity
@en
EGFR-targeted therapies in lung cancer: predictors of response and toxicity.
@nl
P2860
P356
P1433
P1476
EGFR-targeted therapies in lung cancer: predictors of response and toxicity
@en
P2093
David Christiani
Rebecca Suk Heist
P2860
P356
10.2217/14622416.10.1.59
P577
2009-01-01T00:00:00Z